HOLLISTON – Harvard Bioscience has announced plans to close its Holliston manufacturing facility as part of what the company is calling a “strategic consolidation” of its operations.
In a statement released late last week, the company said it plans to transition its U.S. manufacturing operations to Minneapolis. The move is expected to take about a year, with the Holliston facility remaining operational through the end of 2026.
Company officials did not specify what the closure will mean for employees at the Holliston site. However, Harvard Bioscience says the consolidation is expected to result in approximately $4 million in annual cost savings once completed.
The company says additional details about the transition will be shared as the process moves forward.
